New Analyst Forecast: $JANX Given $65.0 Price Target - Nasdaq
5 days ago • Google News
Janux Therapeutics Inc (JANX)
US$ 25.3299-2.8%
Price Chart
Key Statistics
Market Cap
$ 1.52B
P/E Ratio
0.00
Revenue (TTM)
$ 9.34M
Volume
1.25M
52W High
$ 71.71
52W Low
$ 22.48
Dividend Yield
0.00%
Beta
2.96
Technicals
50-Day MA
24.9858
200-Day MA
38.6891
52 Week High
71.71
52 Week Low
22.48
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms t.
Employees
91
Headquarters
San Diego, CA
CEO
Dr. David Alan Campbell Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg